Szkutnik-Fiedler, Danuta
Szałek, Edyta
Otto, Filip http://orcid.org/0000-0002-7418-7555
Czyrski, Andrzej
Karaźniewicz-Łada, Marta
Wolc, Anna
Grześkowiak, Edmund
Lewandowski, Konrad
Karbownik, Agnieszka
Funding for this research was provided by:
Narodowe Centrum Nauki (DEC-2021/05/X/NZ7/01292)
Article History
Received: 18 October 2023
Revised: 26 January 2024
Accepted: 29 January 2024
First Online: 18 April 2024
Declarations
:
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The funders had no role in the design of the study, the collection, analyses, or interpretation of data, the writing of the manuscript, or the decision to publish the results. Anna Wolc, declare that her employment at Hy-Line International (a poultry breeding company) does not create conflict of interest for the publication entitled “Pharmacokinetic interaction between regorafenib and atorvastatin in rats”. Hy-Line Int. doesn’t have any financial interests in pharmacology and had no input or influence on the results from this study.
: The study was conducted according to EU Directive 2010/63/EU on the protection of animals used for scientific purposes and a protocol approved by the Local Ethics Committee (consent No. 32/2022 of 27 May 2022), Department of Animal Physiology and Biochemistry, Poznań University of Life Sciences, ul. Wołyńska 35, 60-637 Poznań, Poland.